Development of renal disease in <font color="blue">people_4</font> <font color="blue">at_4</font> <font color="blue">high_4</font> <font color="blue">cardiovascular_4</font> <font color="blue">risk_4</font> <font color="blue">:_4</font> results of the HOPE randomized study . 
<br>
<br> In <font color="blue">people_3</font> <font color="blue">with_3</font> <font color="blue">diabetes_3</font> <font color="blue">,_3</font> renal disease tends to progress from microalbuminuria to clinical proteinuria to renal insufficiency . Little evidence has been published for the <font color="blue">nondiabetic_2</font> <font color="blue">population_2</font> <font color="blue">._2</font> This study retrospectively analyzed changes of proteinuria over 4.5 yr in the <font color="blue">HOPE_1</font> <font color="blue">(_1</font> <font color="blue">Heart_1</font> <font color="blue">Outcomes_1</font> <font color="blue">and_1</font> <font color="blue">Prevention_1</font> <font color="blue">Evaluation_1</font> <font color="blue">)_1</font> <font color="blue">study_1</font> <font color="blue">,_1</font> which compared ramipril 's effects to placebo in <font color="blue">9297_4</font> <font color="blue">participants_4</font> <font color="blue">,_4</font> <font color="blue">including_3</font> <font color="blue">3577_3</font> <font color="blue">with_3</font> <font color="blue">diabetes_3</font> <font color="blue">and_3</font> <font color="blue">1956_3</font> <font color="blue">with_3</font> <font color="blue">microalbuminuria_3</font> <font color="blue">._3</font> <font color="blue">This_1</font> <font color="blue">report_1</font> <font color="blue">is_1</font> <font color="blue">restricted_2</font> <font color="blue">to_2</font> <font color="blue">7674_5</font> <font color="blue">participants_5</font> <font color="blue">with_4</font> <font color="blue">albuminuria_4</font> <font color="blue">data_4</font> <font color="blue">at_4</font> <font color="blue">baseline_4</font> <font color="blue">and_4</font> <font color="blue">at_4</font> <font color="blue">follow_4</font> <font color="blue">-_4</font> <font color="blue">up_4</font> <font color="blue">._4</font> <font color="blue">Inclusion_1</font> <font color="blue">criteria_1</font> <font color="blue">were_1</font> <font color="blue">known_1</font> <font color="blue">vascular_1</font> <font color="blue">disease_1</font> <font color="blue">or_1</font> <font color="blue">diabetes_1</font> <font color="blue">plus_1</font> <font color="blue">one_1</font> <font color="blue">other_1</font> <font color="blue">cardiovascular_1</font> <font color="blue">risk_1</font> <font color="blue">factor_1</font> <font color="blue">,_1</font> <font color="blue">exclusion_1</font> <font color="blue">criteria_1</font> <font color="blue">included_1</font> <font color="blue">heart_1</font> <font color="blue">failure_1</font> <font color="blue">or_1</font> <font color="blue">known_1</font> <font color="blue">impaired_1</font> <font color="blue">left_1</font> <font color="blue">ventricular_1</font> <font color="blue">function_1</font> <font color="blue">,_1</font> <font color="blue">dipstick_1</font> <font color="blue">-_1</font> <font color="blue">positive_1</font> <font color="blue">proteinuria_1</font> <font color="blue">(_1</font> <font color="blue">>_1</font> <font color="blue">1_1</font> <font color="blue">+_1</font> <font color="blue">)_1</font> <font color="blue">,_1</font> <font color="blue">and_1</font> <font color="blue">serum_1</font> <font color="blue">creatinine_1</font> <font color="blue">>_1</font> <font color="blue">2.3_1</font> <font color="blue">mg_1</font> <font color="blue">/_1</font> <font color="blue">dl_1</font> <font color="blue">(_1</font> <font color="blue">200_1</font> <font color="blue">microM_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> Baseline microalbuminuria predicted subsequent clinical proteinuria for the study participants overall ( adjusted odds ratio [ OR ] , 17.5 ; 95% confidence interval [ CI ] , 12.6 to 24.4 ) , in participants without diabetes ( OR , 16.7 ; 95% CI , 8.6 to 32.4 ) , and in participants with diabetes ( OR , 18.2 ; 95% CI , 12.4 to 26.7 ) . Any progression of albuminuria ( defined as new microalbuminuria or new clinical proteinuria ) occurred in 1859 participants ; 1542 developed new microalbuminuria , and 317 participants developed clinical proteinuria . Ramipril reduced the risk for any progression ( OR , 0.87 ; 95% CI , 0.78 to 0.97 ; P = 0.0146 ) . <font color="blue">People_1</font> <font color="blue">without_1</font> <font color="blue">and_1</font> <font color="blue">with_1</font> <font color="blue">diabetes_1</font> who are at high risk for cardiovascular disease are also at risk for a progressive rise in albuminuria . Microalbuminuria itself predicts clinical proteinuria in <font color="blue">nondiabetic_2</font> <font color="blue">and_2</font> <font color="blue">in_2</font> <font color="blue">diabetic_3</font> <font color="blue">people_3</font> <font color="blue">._2</font> Ramipril prevents or delays the progression of albuminuria .